Brokerages Set Billiontoone, Inc. (NASDAQ:BLLN) Target Price at $135.29

Billiontoone, Inc. (NASDAQ:BLLN) has earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $135.2857.

A number of brokerages recently issued reports on BLLN. William Blair began coverage on Billiontoone in a research note on Monday, December 1st. They set an “outperform” rating for the company. JPMorgan Chase & Co. reduced their target price on Billiontoone from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 10th. Zacks Research raised shares of Billiontoone to a “hold” rating in a research note on Tuesday, December 2nd. Stifel Nicolaus began coverage on shares of Billiontoone in a report on Monday, December 1st. They issued a “buy” rating and a $145.00 price target on the stock. Finally, Guggenheim initiated coverage on shares of Billiontoone in a research note on Tuesday, January 6th. They issued a “buy” rating and a $120.00 price target on the stock.

Institutional Trading of Billiontoone

Several institutional investors and hedge funds have recently modified their holdings of BLLN. FNY Investment Advisers LLC purchased a new stake in shares of Billiontoone in the fourth quarter valued at approximately $497,000. Green Alpha Advisors LLC purchased a new position in Billiontoone during the 4th quarter worth $436,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in Billiontoone during the 4th quarter valued at $13,373,000.

Billiontoone Stock Performance

BLLN stock opened at $90.56 on Tuesday. The stock has a market cap of $4.14 billion and a PE ratio of 905.60. Billiontoone has a 12 month low of $80.00 and a 12 month high of $138.70. The business’s 50-day moving average price is $98.33.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Tuesday, December 9th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.06). The business had revenue of $83.52 million for the quarter, compared to analyst estimates of $82.86 million.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.